Stichworte: LifeWatch AG, New Products, euro adhoc, other Channel: Finanzen
OTE0011   19. Dez. 2012, 17:37

EANS-Adhoc: LifeWatch receives the "Indian Certificate" for its LifeWatch V health smartphone (with document)


ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement.

other/New Products/LifeWatch AG 19.12.2012

Neuhausen am Rheinfall/Switzerland - LifeWatch AG (SIX Swiss Exchange: LIFE), the leading wireless remote cardiac and medical patient monitoring service provider in the U.S., today reports the receipt of the No Objection Certificate from the Central Drugs Standard Control Organization of the Indian Ministry of Health & Family Welfare. LifeWatch may now export and sell the LifeWatch V smartphone across India.

You will find a PDF-version of this press release at the end of this message.

Shortly after being awarded the CE mark for the LifeWatch V health smartphone platform, LifeWatch can today report another milestone for its state-of-the-art device dedicated to health and wellness conscious consumers. The Central Drugs and Standard Control Organization of the Indian Ministry of Health & Family Welfare in New Dehli has granted the No Objection Certificate ("NOC") for the LifeWatch V health smartphone. This certificate allows LifeWatch to export and sell the device across India.

The LifeWatch V is a fully featured state-of-the-art smartphone that allows patients and health- and wellbeing-conscious consumers to self-operate a wide range of embedded medical sensors, wellness-related applications, cloud-based services and 24/7 call center support. By using the barely visible sensors on the phone's frame, users can track, capture, collect and analyze their health measurements anywhere anytime. The sensors include ECG, body temperature, blood glucose, heart rate, blood oxygen saturation, body fat percentage and stress analysis measurement. All of the collected data can be retrieved from the cloud for a follow-up. Users can take corrective action, plan diets and activities, securely share the information with a health provider or family member, trend and analyze the data and more. Patients may also program the LifeWatch V to remind them of their drug type, dose and intake time.

The LifeWatch V smartphone is an important milestone on the Company's way towards more diversification into new service areas such as the consumer and wellness markets and into new geographies. With the NOC certificate, LifeWatch can enter the Indian marketplace which is considered one of the most important future healthcare markets in the world.

"Our receipt of the NOC is another important step in the go-to-market strategy of the LifeWatch V smartphone, and closely follows our announcement of being rewarded the CE mark in the beginning of December 2012", stated Dr. Yacov Geva, Chairman of LifeWatch AG. "This latest approval demonstrates again our capacity to develop and manufacture devices that meet commercial regulatory requirements not only in the U.S. but also in important emerging markets like India".

About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare technology and solution company, specializing in advanced telehealth systems and wireless remote patient monitoring services. LifeWatch services cater to individuals, ranging from high-risk and chronically ill patients, to consumers of health and wellness products. LifeWatch AG has operative subsidiaries in the United States, in Switzerland and in Israel and is the parent company of LifeWatch Services Inc., and LifeWatch Technologies, Ltd. LifeWatch Services, Inc. is a leading US-based provider of cardiac monitoring services and home sleep testing of Obstructive Sleep Apnea (OSA). LifeWatch Technologies Ltd., based in Israel, is a leading developer and manufacturer of telemedicine products. The Company is planning to introduce the LifeWatch V, an Android-based smartphone with medical sensors and apps that uses a cloud-based service platform. For additional information, please visit {www.lifewatch.com}[HYPERLINK: http://www.lifewatch.com].

Sign-up for customized email alerts and documentation requests is available at http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding future results of operations and financial position, business strategy and plans and objectives for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. LifeWatch AG has based these forward-looking statements largely on current expectations and projections about future events and financial trends that it believes may affect the financial condition, results of operations, business strategy, short term and long term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. All forward-looking statements are based only on data available to LifeWatch AG at the time of the issue of this press release. LifeWatch AG does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE ISSUER.

end of announcement   euro adhoc

 Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/IPI4rsuU
issuer:      LifeWatch AG
             Rundbuckstrasse 6
             CH-8212 Neuhausen am Rheinfall
phone:       +41 52 632 00 50
FAX:         +41 52 632 00 51
mail:        users@lifewatch.com
WWW:         www.lifewatch.com
sector:      Healthcare Providers
ISIN:        CH0012815459
indexes:     SPI, SPIEX

stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard: SIX Swiss Exchange language: English

Digital press kit: http://www.ots.at/pressemappe/EASY_100017242/aom

***ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER***

OTE0011 2012-12-19/17:37

OTS-Originaltext Presseaussendung unter ausschließlicher inhaltlicher Verantwortung des Aussenders.
OTE0011 2012-12-19 17:37 191737 Dez 12 EAE0006 1155



LifeWatch AG Zur Pressemappe

Rückfragehinweis: Sensus Communication Consultants,
Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email lifewatch@sensus.ch

Aussendungen von LifeWatch AG abonnieren: als RSS-Feed per Mail



Errechnete Personen: